Stallergenes has secured a long-term agreement to distribute Aerocrineâs airway inflammation monitor and test Kit. The agreement will initially cover France, Italy, Poland, Turkey and the Middle East and could be extended to additional countries.
The agreement, which comes into effect on 1st September 2012, gives Stallergenes exclusive rights for the marketing, sales and distribution of Aerocrineâs instrument Niox Mino and test kits, used for diagnosing and monitoring patients with asthma. Aerocrine's existing distribution with Thermo Fisher Scientific/Phadia, which covers France and Italy, will be terminated on the effective date of this new agreement.
Aerocrineâs compact hand-held NO monitoring device is intended for routine measurements within research and clinical applications, where it can be used to improve the management of asthma and other inflammatory airway conditions in both specialist and primary care clinics. Niox Mino claims added advantages for patient care, including detecting of eosinophilic airway inflammation, determining the likelihood of corticosteroid responsiveness, monitoring of airway inflammation to determine the potential need for corticosteroid, and unmasking of otherwise unsuspected non-adherence to corticosteroid therapy.